Summit Notebook

Exclusive outtakes from industry leaders

AUDIO-Society expectations on side effects weighing on FDA-Shire CEO

November 13, 2007

shire.jpgIndustry critics of the FDA often charge the agency is too conservative and under funded.

But Shire Pharmaceuticals CEO Matthew Emmens tells the Reuters Health Summit there is an unrealistic expectation by society about complex drugs on the market that is making the regulatory environment  that much tougher. 

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
  •